FINHUB Insights

BDX · Q2 FY26 · Mar 31, 2026

Becton Dickinson Q2 FY26: where the revenue came from and where it went

Becton Dickinson Q2 FY26: revenue $4.7B (+5% year over year). Net profit $-0.3B. Largest cohort Medical Essentials $1.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
May 7, 2026 10-Q
Sankey diagram of Becton Dickinson's income statement for Q2 FY26: revenue of $4.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$4.7B +5% year over year
Gross profit$2.2B 46% margin
Operating profit$0.1B 2% margin
Net profit$-0.3B -7% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 4.7 100% +5%
Medical Essentials 1.6 34% +5%
Interventional 1.4 30% +7%
Connected Care 1.1 23% +5%
Bio Pharma Systems 0.6 13% +3%
Cost of revenue−2.655%
Gross profit2.246% margin+4pp
Research & development−0.25%+0pp
SG&A−1.326%+1pp
Other−0.613%+0pp
Operating profit0.12% margin−7pp
Tax−0.1
Interest & other costs−0.3
Net profit-0.3-7%−13pp
Filing on EDGAR More quarters of BDX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters